Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).

被引：11
|
作者：
Jones, Jeffrey Alan
Robak, Tadeusz
Wach, Malgorzata
Brown, Jennifer R.
Menter, Alexander R.
Vandenberghe, Elizabeth
Ysebaert, Loic
Wagner-Johnston, Nina D.
Polikoff, Jonathan
Awan, Farrukh Tauseef
Badoux, Xavier Camille Albert
Coutre, Steven
Spurgeon, Stephen Edward Forbes
Loscertales, Javier
Dreiling, Lyndah
Xing, Guan
Peterman, Sissy
Dubowy, Ronald L.
Flinn, Ian
Owen, Carolyn
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[2] Med Univ Lodz, Lodz, Poland
[3] Med Univ Lublin, Lublin, Poland
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Kaiser Permanente Med Grp, Denver, CO USA
[6] St James Hosp, Dublin, Ireland
[7] CHU Toulouse, Toulouse, France
[8] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[9] Kaiser Hosp San Diego, San Marcos, CA USA
[10] St George Hosp, Cammeray, Australia
[11] Stanford Univ, Stanford, CA 94305 USA
[12] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[13] Hosp Univ La Princesa, Madrid, Spain
[14] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[15] Sarah Cannon Res Inst, Hematol Malignancies Res Program, Nashville, TN USA
[16] Alberta Hlth Serv, Calgary, AB, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7515
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7515
引用
收藏
页数：2
相关论文
共 50 条
  • [21] RANDOMIZED COMPARISON OF IBRUTINIB VERSUS OFATUMUMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA: RESULTS FROM THE PHASE III PCYC-1112 RESONATE(™) TRIAL
    Hillmen, P.
    Brown, J. R.
    O'Brien, S.
    Barrientos, J.
    Kay, N. E.
    Reddy, N. M.
    Coutre, S.
    Tam, C.
    Mulligan, S.
    Jaeger, U.
    Devereux, S.
    Barr, P. M.
    Furman, R.
    Kipps, T.
    Cymbalista, F.
    Pocock, C.
    Thornton, P.
    Caligaris-Cappio, F.
    Robak, T.
    Delgado, J.
    Schuster, S. J.
    Montillo, M.
    Schuh, A.
    DeVos, S.
    Gill, D.
    Bloor, A.
    Dearden, C.
    Moreno, C.
    Jones, J. J.
    Chu, A. D.
    Fardis, M.
    McGreivy, J.
    Clow, F.
    James, D.
    Byrd, J. C.
    HAEMATOLOGICA, 2014, 99 : 244 - 244
  • [22] Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial
    Jones, Jeffrey A.
    Robak, Tadeusz
    Brown, Jennifer R.
    Awan, Farrukh T.
    Badoux, Xavier
    Coutre, Steven
    Loscertales, Javier
    Taylor, Kerry
    Vandenberghe, Elisabeth
    Wach, Malgorzata
    Wagner-Johnston, Nina
    Ysebaert, Loic
    Dreiling, Lyndah
    Dubowy, Ronald
    Xing, Guan
    Flinn, Ian W.
    Owen, Carolyn
    LANCET HAEMATOLOGY, 2017, 4 (03): : E114 - E126
  • [23] Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
    Byrd, John C.
    Hillmen, Peter
    Ghia, Paolo
    Kater, Arnon P.
    Chanan-Khan, Asher
    Furman, Richard R.
    O'Brien, Susan
    Yenerel, Mustafa Nuri
    Illes, Arpad
    Kay, Neil
    Garcia-Marco, Jose A.
    Mato, Anthony
    Pinilla-Ibarz, Javier
    Seymour, John F.
    Lepretre, Stephane
    Stilgenbauer, Stephan
    Robak, Tadeusz
    Rothbaum, Wayne
    Izumi, Raquel
    Hamdy, Ahmed
    Patel, Priti
    Higgins, Kara
    Sohoni, Sophia
    Jurczak, Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (31) : 3441 - +
  • [24] Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma
    Ujjani, Chaitra
    Ramzi, Pari
    Gehan, Edmund
    Wang, Hongkun
    Wang, Yiru
    Cheson, Bruce D.
    LEUKEMIA & LYMPHOMA, 2015, 56 (04) : 915 - 920
  • [25] Phase II trial of the combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)
    Falchi, Lorenzo
    Keating, Michael J.
    Badoux, Xavier C.
    Wierda, William G.
    O'Brien, Susan Mary
    Smith, Susan C.
    Wen, Sijin
    Kantarjian, Hagop
    Ferrajoli, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Combination fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL).
    Garcia-Manero, G
    O'Brien, S
    Cortes, J
    Giles, F
    Faderl, S
    Lerner, S
    Albitar, M
    Kantarjian, HM
    Keating, MJ
    BLOOD, 2000, 96 (11) : 757A - 757A
  • [27] A Phase II Trial Evaluating the Safety of Rapid Infusion Ofatumumab (OFA) in Patients (pts) with Previously Treated Chronic Lymphocytic Leukemia (CLL)
    Donnellan, William B.
    Berdeja, Jesus
    Shipley, Dianna
    Arrowsmith, Edward
    Wright, David
    Lunin, Scott
    Brown, Richard H.
    Essell, James
    Flinn, Ian
    BLOOD, 2014, 124 (21)
  • [28] A Phase 2 Study of Idelalisib Monotherapy in Previously Untreated Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
    Zelenetz, Andrew D.
    Lamanna, Nicole
    Kipps, Thomas J.
    Coutre, Steven E.
    O'Brien, Susan
    Aiello, Maria
    Cho, Yoonjin
    Dubowy, Ronald L.
    Flinn, Ian W.
    BLOOD, 2014, 124 (21)
  • [29] A phase 2 study of idelalisib monotherapy in previously untreated patients ≥ 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
    Zelenetz, Andrew
    Lamanna, Nicole
    Kipps, Thomas
    Coutre, Steven
    O'Brien, Susan
    Graves, Jaime
    Ye, Wei
    Dubowy, Ronald
    Flinn, Ian
    LEUKEMIA & LYMPHOMA, 2015, 56 : 97 - 98
  • [30] A phase 2 study of idelalisib monotherapy in previously untreated patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
    Zelenetz, A.
    Lamanna, N.
    Kipps, T.
    Coutre, S.
    O'Brien, S.
    Graves, J.
    Ye, W.
    Dubowy, R.
    Flinn, I.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 97 - 97
12345